Illumina, Inc.

ILMN Healthcare Diagnostics & Research

Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.

Revenue
+4.15%
EPS
+49.0%
Free cash flow
+49.8%
Total debt
+80.0%

Quarter to September 2026, against a year earlier

212.11 4.11 +1.98%
Market cap
$31.5B
P/E
35.6×
Fwd P/E
46.4×
Dividend yield
—
F-score
8/9
Altman Z
4.39
Beneish M
−2.51
Dividend safety
n/a

Illumina, Inc. 10-Q filed Oct 30, 2026

Fiscal Q3 2026 · Period ended Sep 27, 2026 · Filed · accepted 4:14 PM ET · Document on sec.gov · Filing index

What changed

Part II, Item 1A, Risk Factors, against the 10-Q filed Jul 31, 2026: no comparison — the Item was not found